GH Research PLC (GHRS) stock
GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.27−0.48 (-2.56%)
Close on Nov 17, 2026Market cap $1.13BP/E –Yield –
GH Research cash
Cash and short-term investments held at the end of each period.
GH Research's cash was $345.05M at Jun 30, 2026. For fiscal 2025 it was $246.25M, up 144.3% from the year before. The highest annual figure on record is $276.78M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $246.25M | +144.3% |
| FY2024 | Dec 31, 2024 | $100.79M | +28.5% |
| FY2023 | Dec 31, 2023 | $78.42M | -52.7% |
| FY2022 | Dec 31, 2022 | $165.96M | -40.0% |
| FY2021 | Dec 31, 2021 | $276.78M | +4595.1% |
| FY2020 | Dec 31, 2020 | $5.90M | +1083.7% |
| FY2019 | Dec 31, 2019 | $498.00K | – |
| FY2018 | Dec 31, 2018 | $0 | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $345.05M | +35.9% |
| Q1 FY2026 | Mar 31, 2026 | $242.65M | -0.9% |
| Q4 FY2025 | Dec 31, 2025 | $246.25M | +144.3% |
| Q3 FY2025 | Sep 30, 2025 | $249.65M | +177.2% |
| Q2 FY2025 | Jun 30, 2025 | $253.87M | +191.4% |
| Q1 FY2025 | Mar 31, 2025 | $244.95M | +216.1% |
| Q4 FY2024 | Dec 31, 2024 | $100.79M | +28.5% |
| Q3 FY2024 | Sep 30, 2024 | $90.06M | +4.2% |
| Q2 FY2024 | Jun 30, 2024 | $87.13M | -10.1% |
| Q1 FY2024 | Mar 31, 2024 | $77.48M | -26.3% |
| Q4 FY2023 | Dec 31, 2023 | $78.42M | -52.7% |
| Q3 FY2023 | Sep 30, 2023 | $86.44M | -66.4% |
| Q2 FY2023 | Jun 30, 2023 | $96.90M | -63.5% |
| Q1 FY2023 | Mar 31, 2023 | $105.08M | -62.0% |
| Q4 FY2022 | Dec 31, 2022 | $165.96M | +2715.2% |
| Q3 FY2022 | Sep 30, 2022 | $256.94M | +51494.2% |
| Q2 FY2022 | Jun 30, 2022 | $265.38M | – |
| Q4 FY2021 | Dec 31, 2021 | $276.78M | – |
| Q4 FY2020 | Dec 31, 2020 | $5.90M | – |
| Q4 FY2019 | Dec 31, 2019 | $498.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
See a number that looks wrong?